No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis

Funding source: Novartis Pharma AG, Basel, Switzerland, supported this study. Conflicts of interest: B.E.S. has received honoraria for serving as a consultant and advisory board member for AbbVie, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, LEO Pharma, Medac, Novartis, Pfizer, Stiefel/GlaxoSmithKline, Sun Pharma, UCB and Valeant; has received payments (to the University of Connecticut) as an investigator for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck and Novartis; has received fees as a scientific director for the CORRONA Psoriasis Registry; and has received grant support (to the University of Connecticut for a fellowship programme) from AbbVie and Janssen. R.G.B.L. has been a consultant/advisory board member/paid speaker for AbbVie, Amgen, Celgene, Centocor, Eli Lilly, Novartis and Pfizer. A.M. has served as an investigator for Eli Lilly, Novartis and Wyeth; has served as an investigator for and received research grants from AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Genentech, Janssen Biotech, LEO Pharma, Merck, Pfizer, Symbio/Maruho and Syntrix; and has served as an advisor, consultant and/or speaker for, and received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy Therapeutics, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Novartis, Pfizer, Syntrix, Wyeth and XenoPort. M.M. has been a consultant for Allergan and received honoraria as a speaker for Ipsen Innovation. B.P., T.F., J.S. and C.P. are employees of and own stock in Novartis.